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Abstract
Abnormalities in the enzymatic activity of catechol-O-methyltransferase (COMT) contribute to 
chronic pain conditions, such as temporomandibular disorders (TMD). Thus, we sought to 
determine the effects of polymorphisms in COMT and functionally-related pain genes in the 
COMT pathway (estrogen receptor 1: ESR1, guanosine-5-triphosphate cyclohydrolase 1: GCH1, 
methylenetetrahydrofolate reductase: MTHFR) on COMT enzymatic activity, musculoskeletal 
pain, and pain-related intermediate phenotypes among TMD cases and healthy controls. Results 
demonstrate that the COMT rs4680 (val158met) polymorphism is most strongly associated with 
outcome measures, such that individuals with the minor A allele (met) exhibit reduced COMT 
activity, increased TMD risk, and increased musculoskeletal pain. Epistatic interactions were 
observed between the COMT rs4680 polymorphism and polymorphisms in GCH1 and ESR1. 
Among individuals with the COMT met allele, those with two copies of the GCH1 rs10483639 
minor G allele exhibit normalized COMT activity and increased mechanical pain thresholds. 
Among individuals with the COMT val allele, those with two copies of the ESR1 rs3020377 minor 
A allele exhibit reduced COMT activity, increased bodily pain, and poorer self-reported health. 
These data reveal that the GCH1 minor G allele confers a protective advantage among met 
carriers, while the ESR1 minor A allele is disadvantageous among val carriers. Furthermore, these 
data suggest that the ability to predict the downstream effects of genetic variation on COMT 
activity is critically important to understanding the molecular basis of chronic pain conditions.
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Introduction
Catechol-O-methyltransferase (COMT) is a ubiquitously expressed enzyme that regulates 
the bioavailability of catecholamines, playing a key role in maintaining basic physiologic 
functions such as sympathetic tone, mood, and inflammation, that influence pain. Through 
alternative promoters and translation initiation sites, the COMT gene yields two distinct 
proteins: soluble COMT (S-COMT) and membrane-bound COMT (MB-COMT) [42,62]. 
The COMT gene locus is rich with single nucleotide polymorphisms (SNPs), several of 
which have been associated with chronic pain and pain-related phenotypes.
Most COMT genetic association studies have focused on the common rs4680 SNP. The 
rs4680 A allele has been associated with increased susceptibility to post-surgical pain 
[1,24,32], fibromyalgia [3,15,29,44], and arthritis [65]. Additionally, rs4680 has been 
associated with clinically relevant intermediate phenotypes such as experimental pain [72], 
anxiety [23], depression, and attention [67]. The A allele produces a nonsynonymous change 
from valine to methionine at codon 158 (val158met), resulting in a less thermostable enzyme 
with reduced activity [41]. Studies have consistently shown that the met allele codes for a 
25–40% reduction in enzyme activity measured in human red blood cells [53,59,69] and 
tissues [7] as well as in lysates from transfected cells [41,46,56]. Thus, the val158met allele 
represents a major source of individual variation in COMT activity.
More recently, investigators have identified additional polymorphisms in the COMT gene 
locus that, while not independently associated with pain, interact with the val158met allele. 
Haplotypes consisting of one SNP in the S-COMT promoter (rs6269 G/A) and two SNPs in 
the coding region (rs4633 C/T and rs4818 C/G) together with rs4680 G/A have been 
associated with clinical and experimental pain. Specifically, the ATCA and ACCG 
haplotypes have been associated with susceptibility to post-surgical pain [26], fibromyalgia 
[66], and temporomandibular disorders (TMD) [19] as well as experimental pain sensitivity 
[19] and treatment response [60]. In vitro studies have shown that the ACCG haplotype 
codes for an 80% reduction in enzymatic activity due to formation of a stable mRNA 
secondary structure that is more resistant to translation [46]. Thus, SNPs in distinct COMT 
gene loci can act alone or in concert to influence enzyme activity and pain.
Emerging evidence suggests that the size and direction of COMT polymorphic effects can be 
modified by epistatic interactions with genes in convergent molecular pathways. For 
example, the effects of the met allele on disease risk have been shown to be augmented by a 
low activity variant of the methylenetetrahydrofolate reductase (MTHFR) gene, which 
regulates the bioavailability of S-adenosyl-L-homocysteine (SAH; a strong, noncompetitive 
inhibitor of COMT) [45]. Thus, we hypothesize that polymorphisms in MTHFR and 
functionally-related genes implicated in pain, including estrogen receptor 1 (ESR1; which 
regulates COMT gene expression [35,70]) and guanosine-5-triphosphate cyclohydrolase 1 
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(GCH1; a rate-limiting enzyme for a cofactor for catecholamine synthesis [47]), interact 
with polymorphisms in COMT to influence COMT enzymatic activity and pain.
In order to test this hypothesis, the present study characterized the relationship between 
SNPs located in genes of the COMT pathway (COMT, MTHFR, ESR1, and GCH1), COMT 
enzymatic activity, musculoskeletal pain, and related intermediate phenotypes.
Materials and Methods
Subjects
Subjects were 398 white females aged 18–60 years enrolled in a case-control study of TMD. 
These subjects were recruited between 2005–2009 in Chapel Hill, NC, using advertisements 
placed in local newspapers and flyers posted in and around the UNC Health Center, 
including tertiary care clinics that provide treatment for people with chronic orofacial pain. 
All subjects signed written informed consent for experimental protocols and for genotyping 
and biomarker analysis, and gave a blood sample. A detailed overview of recruitment 
protocols including case definition and exclusion criteria has been described previously [57]. 
Briefly, cases (n=200) had to report facial pain for at least five days during the previous two 
weeks and be diagnosed with TMD arthralgia or myalgia following the Research Diagnostic 
Criteria (RDC) for TMD [21]. Digital palpation of muscle and joint cranial sites was 
performed using a force of 0.45 kg. Controls (n=198) had no self-reported history of 
orofacial pain within the preceding six months and no diagnosis for TMD either prior to or 
during the study examination. Enrolment was limited to females due to the higher 
prevalence of TMD in women than men [10], and to whites to avoid problems of population 
stratification in assessing genetic associations.
Assessment of Bodily Pain and Experimental Pain
At the time of the clinical examination, all study subjects were evaluated for the presence of 
bodily pain. Three pounds of digital palpation pressure were applied bilaterally for 2 
seconds to each of the following predefined locations modeled after ACR's 1990 criteria for 
fibromyalgia tender points examination [71]: occiput, trapezius, supraspinatus, lower 
cervical, second rib, lateral epicondyle, knee, gluteal, and greater trochanter. At each 
location, a response of pain to palpation was recorded.
Following the clinical examination, study subjects completed a battery of quantitative 
sensory testing (QST) assessments. First, thermal pain was assessed by applying a thermode 
to the forearm that increased in temperature at a rate of 0.5°C/sec. Thermal pain threshold 
was defined as the temperature at which pain was first reported, while tolerance was defined 
as the highest temperature that could be tolerated (with an upper limit of 50°C). Second, 
central sensitization was assessed using repeated thermal stimuli of 50°C applied to the right 
hand.[49] Pain was rated on a 0–100 numerical rating scale (NRS) after each of 10 pulses, of 
0.5 sec duration repeated once every three seconds. Plots of each subject's pattern of 
response at each temperature were used to derive two summary measures of temporal 
"windup" (highest NRS response minus lowest NRS response and slope of a linear 
regression line fitted for the first five NRS responses) and two summary measures of 
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thermal sensitivity (first NRS and sum of all NRS responses). Third, pressure pain 
thresholds in response to a hand-held pressure algometer [34] were assessed bilaterally at 
two extracranial sites: trapezius muscles and the lateral epicondyle. Pressure threshold at 
each site was recorded as the algometer loading (kg) at which pain was first detected. 
Descriptive characteristics of bodily pain and experimental pain phenotypes measured in 
TMD cases and controls enrolled in this study have been published previously [11,12,57].
Assessment of Self-reported Pain, Health, and Psychological Mood
Subjects completed several questionnaires to assess the severity of their pain and pain-
related traits. Pain intensity and unpleasantness was measured by the Gracely Pain Scale, 
which asks subjects to report their lowest, average, and maximal pain on a scale of 0 to 100 
[28]. Self-ratings of physical and mental health were measured by the Short Form 12 version 
2 (SF-12v2), which asks questions in six domains: global health rating, physical functioning, 
physical roles, emotional functioning, emotional roles, and pain interference. Published 
scoring algorithms [68] were used to compute scores for each domain, ranging from 0 to 
100, with higher values signifying better function and health. Stress was measured by the 
Perceived Stress Scale (PSS), which contains 10 questions about frequency of daily stressors 
on a five-point scale ranging from “never” to “very often” [16]. Responses were summed for 
an overall score. Additional domains of stress were measured by the Symptoms Checklist- 
90 Revised (SCL-90-R), which consists of 90 items that describe a feeling or thought, 
scored on a 5 point scale ranging from “not at all distressed” to “extremely distressed” [17]. 
It provides ratings of psychological distress in nine symptom areas: somatization, obsessive-
compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid 
ideation, and psychoticism. Psychological mood was measured by the Profile of Mood 
States- Bi-Polar (POMS), which consists of 72 questions used to compute six subscales of 
mood-related states (e.g., elated-depressed and energetic-tired) [39]. Descriptive 
characteristics of self-reported pain, health, and psychological mood phenotypes measured 
in TMD cases and controls enrolled in this study have been published previously [11,12,57].
Genotyping
DNA extracted from whole blood donated by study subjects was genotyped by Beckman-
Coulter Genomics (Morrisville, NC) using the Algynomics Pain Research Panel v.1.0 
(http://algynomics.com/pain-research-panel.html). This platform is a dedicated array for the 
targeted assessment of genes involved in acute and chronic pain conditions, utilizing the 
Affymetrix MegAllele platform. The panel genotypes 3295 SNPs in 358 candidate genes 
whose protein products are linked to biological pathways that influence pain transmission, 
inflammatory response, or psychological state. Genotyping calls were checked for quality 
using utilities implemented in PLINK version 1.07. [50] All 398 samples exhibited 
Caucasian ancestry and an overall genotype call rate < 95%. All SNPs used for this study 
exhibited a call rate >95%, minor allele frequency > 1% in either case or control groups, and 
agreement across repeated samples >98%. The potential for population stratification to 
influence association statistics was assessed by calculating the lambda statistic [18]; no 
evidence was found for inflation of test statistics (λ < 1.0).
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This analysis was limited to four genes directly or indirectly involved in regulating COMT 
activity: COMT, ESR1, GCH1, and MTHFR. Within the COMT gene locus, 9 SNPs passed 
quality filters (Supplemental Table 1: table of COMT activity associations). The rs4633 SNP 
also passed quality filters but was in very strong (r2=1.0) LD with rs4680 and so was not 
included in further analysis. Within the ESR1, GCH1, and MTHFR loci, 27, 10, and 7 SNPs, 
respectively, passed quality filters. For the complete list of ESR1, GCH1, and MTHFR 
SNPs, please refer to Supplemental Table 4.
COMT Activity Assay
S-COMT activity was measured in red blood cells (RBCs) following the method of Schultz 
et al. [55] with some modifications [64]. RBCs were hemolyzed in four volumes of 1 mM 
sodium phosphate buffer (instead of water), enzyme incubation was performed in pH 7.4 
(instead of 7.8) for 60 min, using 500 µM of 3,4-dihydroxy benzoic acid (DHBAc; instead 
of 400 µM) as a substrate, and the samples were filtered with 0.45 µM pore size membranes 
using syringe before HPLC. In principle, vanillic acid generated from the DHBAc substrate 
was quantified with a HPLC system. It consisted of a sample autoinjector (Shimadzu, 
Prominence SIL-20AC, Kyoto, Japan), a pump (Jasco pu- 2080, Tokyo, Japan), an RP-18 
column (3 µm, 4.6 × 100 mm; Waters Spherisorb, Milford, MA, USA) with precolumn, 
column heater (Croco-Cil, Bordeaux, France), a coulometric detector (ESA model 
Coulochem III detector and a model 5011A cell; ESA Inc., Chelmsford, MA, USA; E1 
detector potential was −0 V and that of E2 analytical detector +0.5 V) and Azur 5.0 software 
(Datalys, France). The mobile phase consisted of 0.1 M Na2HPO4 (pH 3.3), 0.15 mM 
EDTA and 25% methanol; the flow-rate was 1.0 ml/min. The protein levels of the samples 
were analyzed using the Bradford assay [8]. COMT activity was expressed as pmol of 
vanillic acid formed per mg of protein in one minute.
This RBC-COMT assay has been validated with human samples containing either normal or 
low COMT levels. Intra-assay coefficient of variation (CV%) was typically <5% and in 
inter-assay <15%. Assay was highly linear for vanillic acid (r = 0.9996–0.9998) and 
precision CV% for vanillic acid was 0.3% at 2 µM and 4.8% at 0.2 µM.
Statistical Analysis
Genetic association analyses were performed using PLINK and JMP, Version 7 (SAS 
Institute Inc., Cary, NC) software packages. Haplotype phasing was performed in PLINK, 
using COMT SNPs rs6269 and rs4633 to construct haplotypes Low Pain Sensitivity (LPS), 
Average Pain Sensitivity (APS), and High Pain Sensitivity (HPS), as described previously.
[19] The phasing algorithm succeeded in phasing all haplotypes and diplotypes with no 
ambiguity. Association tests were conducted by logistic (for binary case-status variables) or 
linear (for quantitative variables) regression, to test the null hypothesis that outcome 
measures were equal between genotype groups. Regression models included age as a 
covariate for variables that were associated with age in a univariate analysis.
Primary analyses were conducted to explore the relationship between COMT, ESR1, GCH1, 
and MTHFR genotype with COMT activity and case status. We first assessed the effects of 
all genotyped COMT polymorphisms and haplotypes of COMT on erythrocyte COMT 
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activity, using a codominant model. For subsequent analyses of COMT genetic effects and 
epistasis, we used the SNP rs4680 (val158met), which results in high activity (valine) and 
low activity (methionine) variants of COMT. To follow the usual convention regarding 
variant effect direction, statistical analyses on this SNP considered the val allele as the 
referent and the met allele as the variant, although in this sample the met allele was actually 
more frequent. We also analyzed SNPs in three COMT pathway genes, MTHFR, ESR1, and 
GCH1, using univariate tests of association. For these SNPs, we screened codominant 
genetic models and compared our results with previous reports in the literature showing 
evidence for alternate models of inheritance. We then constructed 2-way interaction models 
between rs4680 and SNPs within MTHFR, ESR1, and GCH1 to identify SNPs in these genes 
that modulate the effects of val158met on COMT activity and TMD risk, and selected the 
SNP in each gene with the strongest evidence for interaction. For clarity of presentation, we 
modeled interaction effects by testing genotype differences in pathway gene SNPs within 
carriers of either val (for ESR1) or met (for GCH1).
Secondary analyses were also conducted to explore the relationship between COMT 
pathway genotypes and intermediate phenotypes relevant to TMD. We tested the effects of 
SNPs in COMT, ESR1, GCH1, and MTHFR on intermediate variables of pain sensitivity and 
psychological distress. Finally, exploratory analyses were conducted to test for epistatic 
effects of val158met and selected SNPs in ESR1 and GCH1 on COMT activity and TMD 
risk. We constructed a 3-way interaction model that contained three main effect terms for 
val158met, rs3020377 (dominant), and GCH1 (recessive); three 2-way interaction terms for 
each pairwise combination of the three loci; and one 3-way interaction term.
For analyses of genetic association, we set the threshold for significance at an uncorrected p-
value of p<0.05. Although this does not account for the number of tests performed, the 
purpose of the study was to characterize the interactive effects of multiple genes on an array 
of nociceptive and affective phenotypes in order to detect consistent patterns among 
genotype groups. The analyses were designed to reproduce previous significant findings and 
extend them by investigating more complex epistatic interactions in a broad set of outcome 
measures. However, given the increased risk of false positives, novel results should be 
considered exploratory until confirmed in independent cohorts.
Results
Primary analyses were focused on exploring the relationship between COMT, ESR1, GCH1, 
and MTHFR genotype with COMT activity and case status. Secondary analyses were 
focused on exploring the relationship between these COMT pathway genotypes and 
intermediate phenotypes (e.g., pain and mood) relevant to TMD.
Effect of COMT genotype on COMT activity
COMT activity level was strongly associated (p<0.001) with almost all of the COMT SNPs, 
including rs4680 val158met, (Supplementary Table 1) as shown previously 
[7,41,46,53,56,59,69]. Each additional copy of the met allele resulted in a 0.31 pmol/min/mg 
protein decrease in measured COMT activity (Fig. 1A). Haplotype analysis likewise showed 
that the subjects homozygous for the APS haplotype (which contains met at rs4680) had the 
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lowest COMT activity, while subjects with two copies of LPS or HPS (which contain val at 
rs4680) had the highest activity (Supplementary Fig. 1).
The independent effects of the individual SNPs are confounded by linkage disequilibrium 
with val158met, the SNP with the largest effect on COMT activity (Fig. 1B), so each SNP 
was tested in a regression model that included terms for a main effect of rs4680 and an 
interaction between rs4680 and the respective SNP. After adjustment for val158met, most of 
the SNPs failed to show an independent effect on COMT (Fig. 1C and Supplementary Table 
1), although the direction of effect of several SNPs that appeared to increase COMT activity 
showed a smaller effect in the opposite direction. For the representative SNP rs737865, the 
presence of one or two copies of the minor G allele decreased COMT activity across all 
genotypes of val158met (Fig. 1D), with an overall effect of −0.07 pmol/min/mg protein per 
copy of the G allele (p < 0.001). No COMT SNPs showed a significant interaction with 
val158met.
Effect of val158met on pain phenotypes
In addition to COMT activity, we tested association between rs4680 and the primary 
outcome measure of TMD case status (Supplementary Table 2). The SNP was associated 
with TMD after adjustment for age, with the val allele being protective (OR = 0.72, p = 
0.032). We also examined the effects of this SNP on a battery of QST and psychosocial 
profile measures, as a secondary descriptive analysis. Of these intermediate variables, only 
tests of sensitivity to mechanical pressure were significantly associated, including pressure 
point thresholds taken at temporalis (age-adjusted beta = −0.13, p = 0.027), masseter (age-
adjusted beta = −0.14, p = 0.026), TMJ (beta = −0.13, p = 0.037) and lateral epicondyle 
(beta = −0.24, p = 0.007) sites.
Effect of ESR1, GCH1, and MTHFR genotype on COMT activity
Three genes contained in the genotyping panel in addition to COMT were selected for 
analysis due to their known involvement in COMT regulation and pain: ESR1, GCH1, and 
MTHFR. We examined 43 SNPs from these genes for genotype effects on COMT enzymatic 
activity (Supplementary Table 3). Three SNPs from the ESR1 gene were associated with 
COMT activity, including rs3020377 (beta = −0.05, p = 0.04), rs726281 (beta = −0.06, p = 
0.02) and rs3020407 (beta = −0.06, p = 0.02) (Fig. 2). These SNPs are correlated due to 
moderate LD between them (Supplementary Fig. 2), and likely represent a single effect.
2-way interactions on COMT activity: COMT × ESR1/GCH1/MTHFR
The val158met polymorphism exerts the greatest regulatory effect on COMT enzymatic 
activity, but the magnitude of this effect may be modified by other genes in convergent 
pathways. In order to identify variants that modulate the effect of val158met on COMT 
activity, 2-way interaction models were constructed between this SNP and the SNPs in the 
selected COMT pathway genes (Supplementary Table 3). In MTHFR, two SNPs showed 
interaction (p<0.01): rs2274976, an arg594gln non-synonymous change, and rs2066470, a 
pro39pro synonymous variant. There was no significant interaction with rs1801133 
(p=0.48), which has been previously shown to interact with val158met to influence 
schizophrenia risk [45]. Two SNPs in ESR1 exceeded the p<0.05 threshold for the 
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interaction, including rs6912184 (p=0.049) and rs1884052 (p=0.035). The SNPs associated 
with COMT activity in the previous main effect analysis did not show interaction with 
val158met. However, further analysis of the SNP rs3020377 using a dominant model showed 
that carriers of the minor G allele had significantly lower levels of COMT activity in val 
carriers (p=0.0021), but no difference in met carriers. In GCH1, rs10483639 was the most 
strongly associated (p=0.003) in a locus of three neighboring SNPs (including rs752688, 
rs4411417, rs8007201) in the same haploblock (Supplementary Fig. 1b).
We selected one SNP from each of the three genes to carry forward to analysis of pain and 
pain-related intermediate phenotypes. In this selection step, in deciding between SNPs 
showing strong association test p-values, we prioritized SNPs with existing evidence for 
biological relevance to COMT activity and nociceptive pathways. For MTHFR, none of the 
associated SNPs were previously shown to interact with COMT; rs2066470 was chosen 
because it was the SNP with the highest MAF among those with strong interaction test p-
values, in order to maximize power to see effects in subjects carrying the minor allele. The 
ESR1 SNP rs3020377 was selected due to a strong effect on COMT activity in the high-
activity val group alone, as well as a previous report that this SNP interacts with val158met 
to influence endocrine-dependent mood disorders [33]. For GCH1, rs10483639 was selected 
as it showed a strong interaction with val158met, and because it is a marker of a risk 
haplotype identified previously [43]. This haplotype was reported to have a recessive 
inheritance, so for consistency with these findings we used this model for subsequent 
association tests with rs10483639.
Effect of ESR1 genotype on COMT activity and pain phenotypes among COMT (val) 
carriers
The significant difference between ESR1 rs3020377 genotypes within val carriers suggests 
that variation in the estrogen receptor gene modulates COMT enzymatic activity in subjects 
with a genetic predisposition toward high activity due to the rs4680 val allele, but does not 
affect COMT activity in subjects with overall low activity (Fig. 3A). We investigated this 
interaction model in the panel of pain-related phenotypes. We observed similar interactions, 
with effects in carriers of the val allele, in several clinical measures of pain. Relative to val 
carriers with no copies of the rs3020377 minor G allele, subjects with 1 or 2 copies of the G 
allele reported higher scores on the SF12 physical functioning subscale (p = 0.017, Fig. 3B), 
as well as higher pain intensity (p = 0.018, Fig. 3C) and a trend toward higher pain 
unpleasantness ratings (p = 0.07, Fig 3D) using the Gracely Scale. The number of body sites 
with pain upon palpation was also higher in val carriers with 1 or 2 copies of the G allele, 
although this trend was nonsignificant (p=0.08, Fig. 3E).
Effect of GCH1 genotype on COMT activity and pain phenotypes among COMT (met) 
carriers
In contrast with the ESR1 modulatory effect observed in val carriers, modulatory effects of 
the GCH1 SNP were observed within carriers of the rs4680 met allele. Subjects with 0 or 1 
copy of the minor C allele of rs10483639 had significantly lower levels of COMT activity (p 
= 0.0030) than homozygous carriers of the C allele (Fig. 4A). These subjects also had a 
reduced threshold for algometer pressure pain across all tested sites, although only the 
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association with the temporalis site was significant (p = 0.031, Fig. 4B). However, subjects 
that were homozygous for C were more likely to score negatively on measures of mood and 
affect, including the depression (p = 0.025, Fig. 4C) and hostility (p = 0.017, Fig. 4D) 
subscales of the SCL90, the elated-depressed (p = 0.016, Fig. 4E) and energetic (p = 0.025, 
Fig. 4F) axes of the POMS, and the distress domain on the PSS (p = 0.038, Fig. 4G). These 
subjects also reported a decreased ability to function in daily life due to emotional problems 
on the SF12 (p = 0.049, Fig. 4H).
Effect of MTHFR genotype on COMT activity and pain phenotypes among COMT (val/met) 
carriers
Interaction tests were also performed between the MTHFR SNP rs2066470 and val158met as 
with the ESR1 and GCH1 SNPs, with strong effects observed in met carriers between 
rs2066470 genotypes on multiple clinical, affective, and molecular phenotypes. However, 
despite selecting this SNP due to its relatively greater MAF within the gene locus, there 
were still not enough subjects to make statistical comparisons between genotype groups 
(data not shown).
Three gene interaction on COMT activity and TMD risk
Finally, we constructed 3-way genetic interaction models to evaluate the main effects and 
interactions of COMT val158met, ESR1 rs3020377 (using a dominant model), and GCH1 
rs10483639 (recessive) on COMT enzymatic activity and TMD risk. We did not include 
MTHFR in further tests of epistasis due to low frequency of the minor allele of the selected 
SNP. Significant effects were observed on COMT activity (Fig. 5A) for the main effects of 
the COMT (p < 0.001) and ESR1 (p=0.013) SNPs, and the interaction term for COMT × 
GCH1 (p = 0.029); a trend for an association for COMT × ESR1 approached significance (p 
= 0.058). The 3-way interaction term was not significant (p = 0.75). For the TMD variable 
(Fig. 5B), a pattern was observed of coinciding higher COMT activity and lower TMD risk 
due to variation in GCH1, in the met carriers only. In val carriers, there was an apparent 
relationship between ESR1 and GCH1 on COMT activity, such that the GCH1 major allele 
increased COMT activity in ESR1 major allele homozygotes only, although the GCH1 
minor allele coincided with decreased TMD frequency in both ESR1 groups. However, none 
of the main effect or interaction terms were significantly associated with TMD, so these 
preliminary findings require further investigation in larger cohorts to confirm.
Discussion
COMT plays a critical role in the development and maintenance of pain. Understanding how 
variability at the genetic level maps onto variability at the functional level of this enzyme, 
will provide insight into the molecular mechanisms that drive maladaptive pain conditions, 
such as TMD. Here, we identify SNPs in COMT and ESR1 that are independently associated 
with COMT enzymatic activity. Consistent with our hypothesis, we also identify interactions 
between SNPs in COMT and those in functionally-related genes that influence COMT 
enzymatic activity and pain.
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Polymorphisms in COMT and ESR1 Genes are Independently Associated with COMT 
Enzymatic Activity
Our results demonstrate that the major source of individual variation in COMT activity is 
driven by the val158met allele. The number of met alleles was dose-dependently associated 
with COMT activity, such that individuals with one allele exhibited a 27% reduction and 
those with two alleles exhibited a 55% reduction. These results are consistent with those 
from other studies, demonstrating that the met allele codes for a more thermolabile COMT 
enzyme [7,41,46,53,56,59,69].
Of the remaining 8 COMT SNPs genotyped, only the rs737865 A/G allele independently 
accounted for additional variation in COMT activity. After adjusting for the effects of val/
met, a modest association between rs737865 and COMT activity was revealed, such that 
individuals with two copies of the G allele exhibited a 18.4% reduction. The rs737865 SNP 
is positioned in intron 1 of MB-COMT and, while direct evidence for potential functional 
effects of rs737865 is lacking, the G allele has been associated with decreased COMT 
expression in human brain [9]. Additionally, a clinical study of pain following motor vehicle 
collision demonstrated that a haplotype containing the rs737865 G allele was predictive of 
higher pain interference.
Common COMT haplotypes were also tested for association with COMT activity. While 
previous studies by our group showed that cells expressing the ACCG COMT haplotype 
(constructed from rs6269, rs4633, rs4618, and rs4680) exhibited an 80% reduction in 
COMT activity, here we found no link between COMT haplotype and circulating COMT 
activity. This discrepancy between in vitro and in vivo effects of ACCG haplotype on 
COMT activity is likely due to methodological differences in the two studies. The initial in 
vitro studies established a clear link between ACCG and COMT activity in isolated cell 
lines overexpressing the construct [46]. However, subsequent in vitro studies found that the 
extent by which the ACCG haplotype down-regulated COMT expression was cell line-
dependent [63]. COMT activity as determined in the present in vivo study reflects 
cumulative regulation by a chorus of genetic variants expressed in red blood cells.
Finally, we evaluated SNPs in genes whose products regulate the expression or activity of 
COMT. Of the 43 SNPs in MTHFR, ESR1, and GCH1, we identified 3 SNPs in intron 4 of 
ESR1 that were associated with COMT enzymatic activity. These included the rs3020377 
A/G allele, the rs726281 A/G allele, and the rs3020407 A/G allele. Individuals with one or 
two copies of the rs3020377 minor G allele exhibited an 8% reduction in COMT activity. 
Individuals with the rs726281 or rs3020407 minor G allele exhibited a dose-dependent 
decrease in COMT activity, such that those with one copy had an 8% reduction and those 
with two copies had a 12% reduction. As all three ESR1 SNPs are in close proximity and 
moderate LD, their effects are unlikely to be independent. ESR1 can bind to estrogen 
response elements (EREs) in the promoter region of COMT to downregulate its transcription 
[35,70]. Thus, we speculate that rs3020377 G, rs726281 G, rs3020407 G, or another SNP in 
high linkage with those tested codes for increased levels of ESR1, resulting in the 
subsequent downregulation of COMT.
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Polymorphisms in Genes of the COMT Pathway Interact to Influence COMT Enzymatic 
Activity, Musculoskeletal Pain, and Mood
While several distinct alleles in COMT and ESR1 were independently associated with 
COMT activity, the interaction analyses were focused on val158met because it accounted for 
the greatest degree of individual variation. Our results demonstrate that the net size and 
direction of val/met effects are modified by epistatic interactions with SNPs in convergent 
molecular pathways. We identified a significant interaction between the COMT val158met 
allele and the ESR1 rs3020377 A/G allele. Among individuals with the COMT val allele, 
those with two copies of the ESR1 minor G allele exhibited reduced COMT activity, 
increased bodily pain, and poorer self-reported health. While this is the first study to 
demonstrate an interaction between COMT val and ESR1 rs3020377 with respect to COMT 
activity and pain, our findings are in line with a previous report showing that rs3020377 
interacts with val/val (but not val/met or met/met) to influence risk of premenstrual 
dysphoric disorder [33].
We also identified a significant interaction between the COMT val158met allele and the 
rs10483639 G/C allele, located in the 3’UTR of GCH1. GCH1 is the rate limiting enzyme 
for the synthesis of tetrahydrobiopterin (BH4), which is a cofactor necessary for the 
synthesis of catecholamines and nitric oxide- molecules critical for pain [14,22,52,54]. 
Among individuals with the COMT met allele, those with two copies of the GCH1 minor C 
allele exhibited normalized COMT activity and increased mechanical pain thresholds. The 
pain-protective effects of the C allele are in line with previous findings that a haplotype 
containing rs10483639 C is associated with reduced pain following back surgery and 
reduced analgesic requirements following oral surgery [38,40,61]. The GCH1 haplotype 
produces functional biologic effects, coding for reduced GCH1 gene expression and reduced 
BH4 bioavailability [2]. Reduced BH4, in turn, reduces levels of catecholamines and NO to 
alleviate pain.
In agreement with previous studies [45], we identified a statistical 2-way interaction 
between MTHFR SNPs and val158met on COMT activity. However, there were too few 
subjects carrying the rs2274976 or rs2066470 minor alleles to characterize their effects 
stratified by rs4680 genotype. Although the present cohort was underpowered to investigate 
the interaction on TMD risk and other intermediate phenotypes, it would be valuable to 
explore this finding in a larger study.
Finally, we developed a three gene model that takes into account the sum of COMT 
val158met, GCH1 rs10483639 G/C, and ESR1 rs3020377 A/G allelic effects on COMT 
activity and TMD risk. This model illustrates 1) the protective role of GCH1 rs10483639 C 
on COMT activity and TMD risk among met carriers, 2) the deleterious role of ESR1 
rs3020377 G on COMT activity and TMD risk among val carriers with only 0 or 1 copy of 
the GCH1 rs10483639 C allele, and 3) the correlation between COMT activity patterns and 
TMD risk, such that individuals with lower COMT activity are at greater risk for TMD.
It is important to note that the influence of COMT, GCH1, and ESR1 polymorphisms on 
COMT enzymatic activity is likely modified by environmental events that produce physical 
and emotional stress, inflammation, and/or injury [27,30,51]. An example of gene-
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environment interaction was illustrated by Slade and colleagues, who found that among 
individuals with ATCA or ACCG COMT haplotypes, TMD incidence was 23% for those 
with a history of orthodontic treatment and 0% for those with no history of orthodontic 
treatment [58]. In addition, the influence of genetic polymorphism on COMT activity is 
likely modified by sex. It is well-established that males and females differ with respect to 
COMT activity levels, with males exhibiting higher levels in brain [13] and peripheral 
tissues [7], as well as COMT-dependent nociception [5] and behavioral traits [31]. Further, a 
growing number of studies demonstrate sex-dependent differences in the role of ESR1 SNPs 
[6,25,37] and COMT val/met [4,20,36,48] in disease susceptibility. As the present study 
enrolled only females, we were unable to explore interactions between sex, genotype, and 
COMT activity. Thus, future studies should also account for the effects of sex and 
nongenetic factors on COMT activity and related phenotypes.
Conclusion
In conclusion, polymorphisms located in distinct gene loci can act alone or in concert to 
influence the expression and activity of corresponding pain-relevant molecules such as 
COMT. The COMT val158met allele accounts for the greatest amount of individual variation 
in COMT activity, yet its effects are modified by SNPs in functionally-related ESR1 and 
GCH1 genes. Among individuals with the COMT val allele, those with two copies of the 
ESR1 rs3020377 minor G allele exhibit reduced COMT activity, increased bodily pain, and 
poorer self-reported health. Among individuals with the COMT met allele, those with two 
copies of the GCH1 rs10483639 minor C allele exhibit normalized COMT activity and 
increased mechanical pain thresholds. Thus, the ESR1 minor G allele is deleterious among 
val carriers, while the GCH1 minor C allele confers a protective advantage among met 
carriers. This finding is further confirmed in the three gene model, which also illustrates the 
parallels between low COMT activity and increased TMD risk. Ultimately, measuring 
functional levels of COMT will provide information representing the sum of molecular 
regulatory events affected by genetic polymorphisms as well as environmental events.
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Fig. 1. COMT genotype effects COMT activity
A. COMT val158met genotype effects COMT activity, such that individuals with 1 or 2 
copies of the met allele exhibit reduced activity. Data represent mean ± s.e.m. ***p < 
0.0001. B. Linkage disequilibrium plot of the genotyped SNPs in the COMT gene locus. The 
gene diagram indicates the location of each SNP with respect to exons (boxes) and introns of 
the gene. The color of each box in the LD plot depicts the strength of LD between aligned 
SNPs according to D’ (darker red indicates stronger LD), and the number in the box is the 
corresponding r2 value. C. COMT activity levels of each genotype are shown for all COMT 
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SNPs tested. Symbols and lines are colored green if the respective minor allele is associated 
with increased COMT activity, and red with decreased COMT activity; the rs4680 val158met 
is shown in black. In the top panel genotype effects of each SNP are unadjusted; in the 
bottom panel each SNP effect is adjusted for val158met genotype. D. COMT activity level of 
each genotype of rs737865, stratified by val158met genotype, shows that the minor G allele 
of this SNP is associated with decreased COMT activity after the confounding effect of 
val158met is removed.
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Fig. 2. ESR1 SNP effects on COMT activity
All three ESR1 SNPs showed significant (p<0.05) association with COMT activity using a 
codominant model, although the dominant model provides a better fit for the data for 
rs3020377. Data represent mean ± s.e.m.
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Fig. 3. COMT × ESR1 effects on COMT activity and pain phenotypes
For genotypes of the ESR1 SNP rs3020377, all carriers of the minor G allele were combined 
(dominant test) and stratified by carriers of COMT alleles val and met. Significance level 
shown is that of the test of the G allele carriers against the reference of the major allele 
homozygote group, within val carriers only. Among val carriers, the ESR1 rs3020377 SNP 
produced effects on A. COMT enzymatic activity, B. physical functioning subscale of the 
SF12 questionnaire, C. pain intensity rating using the Gracely scale of the SPSR, D. pain 
unpleasantness rating using the Gracely Pain Scale of the SPSR, and E. count of the number 
of bodily sites painful upon palpation by clinical examiner. For each phenotype, rs3020377 
modulates the effect of the val allele, but not the met allele, of COMT. The G allele of 
rs3020377 decreased COMT activity and physical functioning, and increased nociceptive 
phenotypes of pain intensity, unpleasantness, and distribution across body sites. Data are 
quantitative trait means ± s.e.m. † p < 0.1 * p< 0.05 ** p<0.01.
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Fig. 4. COMT × GCH1 effects on COMT activity and pain phenotypes
The GCH1 SNP rs10483639 showed a recessive mode of inheritance, and was stratified by 
carriers of the COMT alleles val and met. Significance level shown is that of the test of the C 
allele homozygotes against the reference of the major allele carriers, within met carriers 
only. Among met carriers, the GCH1 rs10483639 SNP produced effects on A. COMT 
enzymatic activity, B. algometer pressure at which pain is detected, measured at the 
temporalis muscle, C. depression subscale of the SCL90 questionnaire, D. hostility subscale 
of the SCL90, E. elated-depressed axis of the POMS, F. energetic-tired axis of the POMS. 
G. distress subscale of the PSS, and H. dysfunction in daily activities due to emotional 
factors, measured by the SF12 questionnaire. Carrying two copies of the rs10483639 C 
allele raised COMT activity in met carriers to the level of val carriers, but had no effect in 
the high-activity val carriers. The C allele was associated with higher algometer threshold in 
both val and met carriers, but was associated with more negative psychological 
characteristics in met carriers only. Data are quantitative trait means ± s.e.m. * p< 0.05.
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Fig. 5. Three-way interaction between COMT, ESR1, and GCH1 SNPs on COMT activity and 
TMD risk
A. COMT enzyme activity (means ± s.e.m.) and B. TMD frequency is plotted for each 
genotype. The GCH1 rs10483639 C allele increases COMT activity and reduces TMD risk 
among met carriers, while the ESR1 rs3020377 G allele decreases COMT activity and 
increases TMD risk among val carriers with only 0 or 1 copy of the GCH1 rs10483639 C 
allele.
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Table 1
COMT pathway SNP effects on S-COMT enzymatic activity
Val Met
Beta (S.E.M.) P Beta (S.E.M.) P
rs2066470 (MTHFR) −0.020 (0.03) 0.56 0.080 (0.03) 0.010
rs3020377 dom (ESR1) 0.048 (0.02) 0.0021 0.002 (0.01) 0.87
rs10483639 rec (GCH1) 0.026 (0.03) 0.39 −0.10 (0.03) 0.0030
Selected SNPs showed differential effects on S-COMT activity, based on val158met carrier status. The MTHFR (rs2066470) and GCH1 
(rs10483639) SNPs were associated with S-COMT activity only in the low activity met carriers; the ESR1 (rs3020377) SNP was associated only in 
the high activity val carriers. Data represent the beta coefficient and s.e.m. of the SNP genotype term of a univariate regression model of S-COMT 
activity.
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